Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.4061/2010/612619 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564249215369216 |
|---|---|
| author | Wolfram Eisenreich Bernd Sommer Sebastian Hartter Wolfgang H. Jost |
| author_facet | Wolfram Eisenreich Bernd Sommer Sebastian Hartter Wolfgang H. Jost |
| author_sort | Wolfram Eisenreich |
| collection | DOAJ |
| description | Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October 2009, an extended-release formulation of pramipexole has been available for symptomatic treatment of Parkinson's disease. Pramipexole administration can be cut down from three times to once a day due to the newly developed extended-release formulation. This is considerable progress in regard to minimizing pill burden and enhancing compliance. Moreover, the 24 h continuous drug release of the once-daily extended-release formulation results in fewer fluctuations in plasma concentrations over time compared to immediate-release pramipexole, given three times daily. The present study summarizes pharmacokinetics and all essential pharmacological and clinical characteristics of the extended-release formulation. In addition, it provides all study data, available so far, with regard to transition and de-novo administration of extended-release formulation for patients with Parkinson's disease. It further compares efficacy and safety data of immediate-release pramipexole with the extended-release formulation of pramipexole. |
| format | Article |
| id | doaj-art-2637a8ef81454538881ef8528f0b5750 |
| institution | Kabale University |
| issn | 2042-0080 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-2637a8ef81454538881ef8528f0b57502025-02-03T01:11:24ZengWileyParkinson's Disease2042-00802010-01-01201010.4061/2010/612619612619Pramipexole Extended Release: A Novel Treatment Option in Parkinson's DiseaseWolfram Eisenreich0Bernd Sommer1Sebastian Hartter2Wolfgang H. Jost3Boehringer Ingelheim Pharma GmbH & Co. KG, Pharmaceutical Development, 88397 Biberach, GermanyBoehringer Ingelheim Pharma GmbH & Co. KG, CNS Research, 88397 Biberach, GermanyBoehringer Ingelheim Pharma GmbH & Co. KG, Drug Metabolism and Pharmacokinetics, 88397 Biberach, GermanyDepartment of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, GermanyPramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October 2009, an extended-release formulation of pramipexole has been available for symptomatic treatment of Parkinson's disease. Pramipexole administration can be cut down from three times to once a day due to the newly developed extended-release formulation. This is considerable progress in regard to minimizing pill burden and enhancing compliance. Moreover, the 24 h continuous drug release of the once-daily extended-release formulation results in fewer fluctuations in plasma concentrations over time compared to immediate-release pramipexole, given three times daily. The present study summarizes pharmacokinetics and all essential pharmacological and clinical characteristics of the extended-release formulation. In addition, it provides all study data, available so far, with regard to transition and de-novo administration of extended-release formulation for patients with Parkinson's disease. It further compares efficacy and safety data of immediate-release pramipexole with the extended-release formulation of pramipexole.http://dx.doi.org/10.4061/2010/612619 |
| spellingShingle | Wolfram Eisenreich Bernd Sommer Sebastian Hartter Wolfgang H. Jost Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease Parkinson's Disease |
| title | Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease |
| title_full | Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease |
| title_fullStr | Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease |
| title_full_unstemmed | Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease |
| title_short | Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease |
| title_sort | pramipexole extended release a novel treatment option in parkinson s disease |
| url | http://dx.doi.org/10.4061/2010/612619 |
| work_keys_str_mv | AT wolframeisenreich pramipexoleextendedreleaseanoveltreatmentoptioninparkinsonsdisease AT berndsommer pramipexoleextendedreleaseanoveltreatmentoptioninparkinsonsdisease AT sebastianhartter pramipexoleextendedreleaseanoveltreatmentoptioninparkinsonsdisease AT wolfganghjost pramipexoleextendedreleaseanoveltreatmentoptioninparkinsonsdisease |